Creating a dataset for Age-Related Macular Degeneration imaging
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
This study is collecting eye images from people aged 50 and older to see if a new AI tool can help spot early signs of Age-Related Macular Degeneration and prevent vision loss.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 14 sites (Fargo, North Dakota and 13 other locations) |
| Trial ID | NCT06924021 on ClinicalTrials.gov |
What this trial studies
This observational study involves 1000 participants aged 50 and older from up to 25 international locations, who will provide retinal images to create a benchmark dataset for Age-Related Macular Degeneration (AMD). The goal is to develop an Artificial Intelligence (AI) based screening tool that can identify early stages of AMD, which is crucial for preventing vision loss. Participants can either have healthy eyes or a diagnosis of AMD, and their images will be used to validate AI models for effective screening. The study aims to address the challenges in enrolling sufficient cases for prospective validation of these screening tools.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 50 and older with either healthy eyes or any stage of Age-Related Macular Degeneration.
Not a fit: Patients currently undergoing therapeutic treatment for AMD or those with severe vision loss requiring urgent surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of an AI tool that improves early detection of Age-Related Macular Degeneration, potentially preventing vision loss.
How similar studies have performed: Other studies have shown promise in developing AI-based screening tools for AMD, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants greater than or equal to 50 years of age at time of signing Informed Consent Form * Willing to comply with all study procedures and sign the Informed Consent Form (ICF) * Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center. Exclusion Criteria: * Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed. * Unable to acquire adequate quality images, as evaluated by the Central Reading Center * Severe vision loss requiring urgent surgery * Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light * A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study * Unwilling to sign informed consent form * Currently or previously enrolled in an interventional AMD clinical trial
Where this trial is running
Fargo, North Dakota and 13 other locations
- Bergstrom Eye Research LLC — Fargo, North Dakota, United States (Recruiting)
- Erie Retina Research — Erie, Pennsylvania, United States (Recruiting)
- Retina Foundation of the Southwest — Dallas, Texas, United States (Recruiting)
- Valley Retina Institute — McAllen, Texas, United States (Recruiting)
- Retina Consultants of Texas (Houston) — The Woodlands, Texas, United States (Recruiting)
- University of Utah - John A. Moran Eye Center — Salt Lake City, Utah, United States (Recruiting)
- University Station Eye Care Clinic — Madison, Wisconsin, United States (Recruiting)
- Charles Research Center — Buenos Aires, Argentina (Not_yet_recruiting)
- Adelaide Eye and Retina Centre — Adelaide, Australia (Not_yet_recruiting)
- Centre Hospialier Intercommunal de Paradis (Centre Monticelli Paradis) — Marseille, France (Not_yet_recruiting)
- University of Bonn - Department of Ophthalmology — Bonn, Germany (Not_yet_recruiting)
- Sankara Nethralaya, Medical Research Foundation — Chennai, Tamil Nadu, India (Recruiting)
- Aravind Eye Hospital — Chennai, Tamil Nadu, India (Recruiting)
- Aga Khan University — Karachi, Pakistan (Recruiting)
Study contacts
- Principal investigator: Amitha Domalpally, MD, PhD — UW School of Medicine and Public Health
- Study coordinator: Wisconsin Reading Center
- Email: wrc.support@wisc.edu
- Phone: 1-608-262-1334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.